Healthcare company Perrigo Company plc (NYSE:PRGO) said on Monday that it is the first company to receive approval from the US Food and Drug Administration for its abbreviated new drug application (ANDA) for over-the-counter (OTC) diclofenac sodium topical gel 1% for the treatment of arthritis pain, with a launch later this year.
Through its prescription (Rx)-to-OTC switch process, the US FDA approved the company's Voltaren Arthritis Pain (diclofenac sodium topical gel, 1%) for nonprescription or OTC use .
The company added the product will be marketed under retailer's store brand labels and will provide consumers with a high-quality, value alternative to GSK's Voltaren Arthritis Pain, which is indicated for the temporary relief of arthritis pain.
For the 12 months ending February 2020, the branded and generic prescription sales were USD250, according to IQVIA.
Peak Pharma Commercial Partners establishes Resilia Pharmaceuticals and starts operations
Nephron Pharmaceuticals Corporation receives USFDA approval over Ketorolac Tromethamine Injection
Amring gains global rights to LYSTEDA
Troy Medicare Closes USD 10m Series B Led by AXA Venture Partners
Breckenridge wins final FDA approval for Pomalidomide Capsules ANDA
Amneal Receives Abbreviated New Drug Application Approval for Acyclovir Cream, 5%
Cipla reports sharp rise in demand for COVID-19 drug remdesivir in India
Sandoz ships pantoprazole sodium to Civica Rx
Russia's Pharmasyntez seeks permission to produce COVID-19 drug without patent